Rhythm Pharmaceutical Shares Are Trading Higher After the Company Announced FDA Acceptance for Priority Review of Supplemental NDA for IMCIVREE.
Rhythm Pharmaceutical Shares Are Trading Higher After the Company Announced FDA Acceptance for Priority Review of Supplemental NDA for IMCIVREE.
萊姆藥品股票交易上漲，因公司宣佈IMCIVREE補充新藥申請獲得FDA優先審評。
Rhythm Pharmaceutical Shares Are Trading Higher After the Company Announced FDA Acceptance for Priority Review of Supplemental NDA for IMCIVREE.
萊姆藥品股票交易上漲，因公司宣佈IMCIVREE補充新藥申請獲得FDA優先審評。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。